This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

Home | About the eMC | Help | Mobile

eMC - trusted, up to date and comprehensive information about medicines

Search medicine/company name only

Search full document

Advanced search

Medicine name A-Z | Active ingredient A-Z | Pharmaceutical company A-Z | Latest medicine updates | Yellow card report

Merck Sharp & Dohme Limited

Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU

Telephone: +44 (0)1992 467 272
Fax: +44 (0)1992 479 292
WWW: http://www.msd-uk.com
Medical Information e-mail: medicalinformationuk@merck.com

Stock Availability: Call MSD customer services on 01992 452094

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 18/02/2011

SPC

Diprobath

Table of Contents

1. Name of the medicinal product
2. Qualitative and quantitative composition
3. Pharmaceutical form
4. Clinical particulars
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
4.5 Interaction with other medicinal products and other forms of interaction
4.6 Fertility, pregnancy and lactation
4.7 Effects on ability to drive and use machines
4.8 Undesirable effects
4.9 Overdose
5. Pharmacological properties
5.1 Pharmacodynamic properties
5.2 Pharmacokinetic properties
5.3 Preclinical safety data
6. Pharmaceutical particulars
6.1 List of excipients
6.2 Incompatibilities
6.3 Shelf life
6.4 Special precautions for storage
6.5 Nature and contents of container
6.6 Special precautions for disposal and other handling
7. Marketing authorisation holder
8. Marketing authorisation number(s)
9. Date of first authorisation/renewal of the authorisation
10. Date of revision of the text
11 Legal category

Go to top of the page

1. Name of the medicinal product

Diprobath

Go to top of the page

2. Qualitative and quantitative composition

Light Liquid Paraffin 46.0% w/w

Isopropyl Myristate 39.0% w/w

For a full list of excipients, see section 6.1.

Go to top of the page

3. Pharmaceutical form

Liquid bath emollient

Go to top of the page

4. Clinical particulars

Go to top of the page

4.1 Therapeutic indications

Treatment of dry skin conditions and other hyperkeratoses, including those associated with dermatitis and eczema.

To be diluted in bath water for external application.

Go to top of the page

4.2 Posology and method of administration

Adults including elderly patients :

25ml or approximately 2.5 capsful to be diluted in a bath of water (100 L approximately). For particularly dry skin the quantity of oil emollient may be doubled.

Children :

10ml or one capful is sufficient for children's baths.

Frequency and duration of bathing will depend on the type and severity of the conditions, but generally 2 to 3 baths should be taken weekly.

Go to top of the page

4.3 Contraindications

Known hypersensitivity to any of the ingredients.

Go to top of the page

4.4 Special warnings and precautions for use

As Diprobath deposits a film of oil over the skin, care should be taken to avoid slipping in the bath.

The following warning will appear on the label :

'Take care when entering or leaving the bath which may be more slippery than usual'.

Go to top of the page

4.5 Interaction with other medicinal products and other forms of interaction

None known.

Go to top of the page

4.6 Fertility, pregnancy and lactation

No special precautions.

Go to top of the page

4.7 Effects on ability to drive and use machines

None known.

Go to top of the page

4.8 Undesirable effects

None known.

Go to top of the page

4.9 Overdose

Not applicable.

Go to top of the page

5. Pharmacological properties

Go to top of the page

5.1 Pharmacodynamic properties

Both active ingredients have established emollient properties which are of relevance to use as a bathing emollient.

Go to top of the page

5.2 Pharmacokinetic properties

Pharmacokinetic principles are not involved due to direct topical application.

Go to top of the page

5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

Go to top of the page

6. Pharmaceutical particulars

Go to top of the page

6.1 List of excipients

Laureth-4

Go to top of the page

6.2 Incompatibilities

None Known

Go to top of the page

6.3 Shelf life

24 months

Go to top of the page

6.4 Special precautions for storage

Store upright at a temperature below 30°C.

Go to top of the page

6.5 Nature and contents of container

50 ml and 500 ml: natural opaque high-density polyethylene (HDPE) single neck bottle with a polypropylene screw cap. Mounted in the cap is a polyethylene liner containing a polytetrafluoroethylene (PTFE) venting disc.

Not all pack sizes may be marketed.

Go to top of the page

6.6 Special precautions for disposal and other handling

Not applicable

Go to top of the page

7. Marketing authorisation holder

Merck Sharp & Dohme Limited

Hertford Road

Hoddesdon

Hertfordshire

EN11 9BU

Go to top of the page